Press release
Dermatophytic Onychomycosis Therapeutics Market will surge to a market valuation of US$ 10.30 Bn by the end of 2031 | North America, Europe, APAC Region
Dermatophytic Onychomycosis Therapeutics Market
Additionally, the infection may spread to nearby skin. Although the illness is not thought to be life-threatening, it may pose physical and occupational constraints, which is why an increasing number of people are choosing to have their infected, thick, and cracked nails treated. The market for treatments for dermatophytic onychomycosis is consequently expanding.
Request for Free Sample Copy of Dermatophytic Onychomycosis Therapeutics Market @https://www.persistencemarketresearch.com/samples/5840
Tablets and nail paints, which are further divided into prescription (Rx) and over-the-counter, make up the tablet and nail paint segments of the global market for treatments for dermatophytic onychomycosis. The market for treatments for dermatophytic onychomycosis is anticipated to grow at a CAGR of 8.1% over the course of the forecast period, with the nail paint category projected to provide the largest share.
The global market for dermatophytic onychomycosis therapies has been divided into topical and oral treatment segments based on mode of administration. By 2026, the topical sector is expected to hold a about 70% share of the global market for treatments for dermatophytic onychomycosis, making it the dominating segment throughout the forecast period.
Increase in nail infection diagnoses has increased public knowledge of nail fungus infections and treatments for dermatophytic onychomycosis. In addition, dermatophytic onychomycosis therapies are becoming more widely known among podiatrists and dermatologists, which has increased demand for efficient drugs. However, side effects like headache, nausea, dizziness, and stomach discomfort linked to antifungal medications have made patients less confident about using a systemic therapy for nails.
Additionally, the topical medications also make the skin around the affected area rashy and itchy. The acceptability of dermatophytic onychomycosis treatments for the treatment of mild to severe dermatophytic onychomycosis linked with anti-fungal therapeutics is being hampered by these side effects.
Key Players in the Industry -
• Bausch Health
• Galderma S.A.
• Novartis AG
• Pfizer, Inc.
• Moberg Pharma AB
• Bayer AG
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.
• Medimetriks Pharmaceuticals, Inc.
• Sanofi S.A.
• GlaxoSmithKline Plc.
• Teva Pharmaceutical industries Ltd.
• Cardinal Health Inc.
• Viatris Inc.
• Almirall, S.A
Request for report Customization@ https://www.persistencemarketresearch.com/request-customization/5840
Geographically, the market for therapies for dermatophytic onychomycosis is divided into five main areas: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa (MEA).
Dermatophytic onychomycosis treatments were primarily sold in North America, and this tendency is anticipated to continue over the projected period. Therapeutics for dermatophytic onychomycosis are predicted to see the second-largest market share in Europe, after Asia Pacific.
Over the course of the forecast period, North America and Europe are anticipated to hold over 60% of the global market for treatments for dermatophytic onychomycosis.
Buy Now this Report @https://www.persistencemarketresearch.com/checkout/5840
Persistence market research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatophytic Onychomycosis Therapeutics Market will surge to a market valuation of US$ 10.30 Bn by the end of 2031 | North America, Europe, APAC Region here
News-ID: 2805334 • Views: …
More Releases from Persistence Market Research
Plastic Liner Market to Reach US$ 6.67 Bn by 2030, Expanding at 4.7% CAGR - Pers …
➤ Overview of the Market
The global plastic liner market has gained steady traction across multiple industries due to its cost-effectiveness, versatility, and protective characteristics. Plastic liners are widely used in agriculture, mining, construction, waste management, and packaging industries, where they serve as an essential barrier to prevent leakage, contamination, and material loss. These liners are manufactured using materials such as polyethylene (PE), polypropylene (PP), and PVC, offering superior resistance to…
Returnable Plastic Crate Market to Reach US$ 2,665.1 Million by 2030 Fueled by S …
➤ Overview of the Market
The global returnable plastic crate market is gaining momentum as industries seek cost-effective and sustainable packaging solutions. These crates are widely used for transporting and storing perishable goods, beverages, pharmaceuticals, and industrial products due to their durability, stackability, and reusability. The shift from single-use packaging to eco-friendly alternatives has accelerated the adoption of returnable plastic crates across sectors. The market, valued at US$ 1,820.0 million in…
US Thermal Power Market Expected to Reach US$ 251.9 Mn by 2031 with 2.4% CAGR Gr …
➤Overview of the Market
The US thermal power market plays a crucial role in the nation's energy mix, serving as a stable and reliable source of electricity despite the rise of renewables. Thermal power plants in the US rely primarily on coal, natural gas, and oil to generate electricity, with natural gas emerging as the dominant fuel source due to its affordability, efficiency, and lower carbon footprint compared to coal. According…
Europe Medical Plastic Market to Reach US$ 17 Bn by 2032 Driven by Rising Health …
➤Overview of the Market
The Europe medical plastic market is undergoing robust growth, fueled by increasing demand for lightweight, durable, and cost-effective materials in the healthcare sector. Medical plastics are widely used in devices, surgical instruments, diagnostic tools, implants, and packaging due to their high biocompatibility, versatility, and resistance to sterilization methods. With healthcare systems across Europe investing heavily in modernization and patient safety, the adoption of medical-grade plastics has gained…
More Releases for Dermatophytic
Call for Automation to Drive the Dermatophytic Onychomycosis Therapeutics Market
Advancements in medicine, diagnosis of varieties of illnesses, and increasing elder population at an unprecedented rate have resulted in high demand for novel drugs and therapies for dermatophytic onychomycosis treatment. In 2021, the dermatophytic onychomycosis therapeutics market was valued at nearly US$ 5.5 Bn, and is set to experience a 6.5% CAGR over the forecast period (2022-2031).
Presence and availability of a large clinical pipeline with reference to therapeutic approaches based…
Dermatophytic Onychomycosis Therapeutics (DOT) Market 2022 | Detailed Report
The research reports on “Dermatophytic Onychomycosis Therapeutics (DOT) Market” report gives detailed overview of factors that affect global business scope. Dermatophytic Onychomycosis Therapeutics (DOT) Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. An exclusive data offered in this report is collected by research and industry experts team.
Download FREE Sample…
Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin…
Dermatophytic Onychomycosis Market Expected to Witness a Sustainable Growth
According to a new report published by Allied Market Research, titled, " Dermatophytic Onychomycosis Market by Product (Nail Paint and Tablet), Route of Administration (Topical and Oral Therapy), and End User (Hospitals, Dermatology & Podiatry Clinics, Independent Pharmacies, Mail Order Pharmacies, and Drug Stores) - Global Opportunity Analysis and Industry Forecast, 2020-2027".
The global market size of Dermatophytic Onychomycosis market is $XX million in 2019 with XX CAGR, and it is…
Dermatophytic Onychomycosis Market Poised to Rake US$ 4,706.3 Mn by 2021
Key players of the global dermatophytic onychomycosis therapeutics market include Galderma S.A., Valeant Pharmaceuticals International Inc., Novartis AG, Pfizer Inc., Janssen Pharmaceuticals, and others. Leading companies in this market collaborate with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care.
Persistence Market Research (PMR) delivers key insights on the global dermatophytic onychomycosis therapeutics Market in its latest report titled “Global Market Study on Dermatophytic…
Dermatophytic Onychomycosis Market : Topical segment to account 70% share
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market and expand at the fastest CAGR of 8.3% during the…
